Welcome to LookChem.com Sign In|Join Free
  • or
N-((1-benzyl-1H-imidazol-5-yl)methyl)-N-ethylethanamine is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1417526-45-4

Post Buying Request

1417526-45-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1417526-45-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1417526-45-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,1,7,5,2 and 6 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1417526-45:
(9*1)+(8*4)+(7*1)+(6*7)+(5*5)+(4*2)+(3*6)+(2*4)+(1*5)=154
154 % 10 = 4
So 1417526-45-4 is a valid CAS Registry Number.

1417526-45-4Downstream Products

1417526-45-4Relevant academic research and scientific papers

AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE

-

Paragraph 0249, (2014/05/20)

The present invention relates to the filed of pharmarcutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) amd a preparation method thereof, a pharmarcutical composition with the compounds as active components, and a use of the azole compounds and the pharmarcutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA2 enzyme activities, wherein each substituent is as deinfed in the specifictaion.

AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE

-

Paragraph 0598, (2014/06/25)

The present invention relates to the field of pharmaceutical chemistry, and in particular, to a novel class of azole compounds represented by general formula (I), (II) or (III) and a preparation method thereof, a pharmaceutical composition with the compounds as active components, and a use of the azole compounds and the pharmaceutical composition in the preparation of a medicament for treatment of diseases associated with Lp-PLA2 enzyme activities, wherein each substituent is as defined in the specification.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1417526-45-4